Cite
HARVARD Citation
Wainberg, Z. et al. (n.d.). SO-005A phase 1/2, open-label, dose-expansion study of liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) in patients with previously untreated metastatic pancreatic cancer. Annals of oncology. p. . [Online].